BioNTech maps pivotal oncology milestones for 2026
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
CARsgen is working to transform outcomes for patients with solid tumors by advancing the potential of CAR T technologies
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration
Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
Subscribe To Our Newsletter & Stay Updated